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INTRODUCTION 
Diabetes mellitus considerably contributes to the development and 
the deterioration of lower urinary tract symptoms. Patients with type 2 
Diabetes mellitus are more prone to be diagnosed with benign prostatic 
hyperplasia and subsequently subjected to prostatectomy than general 
male population. This fact signifies that the scientific value of the 
epidemiologic association between benign prostatic hyperplasia and type 
2 Diabetes through lower urinary tract symptoms. 
Diabetes mellitus affects bladder function producing both 
obstructive and irritative symptoms, with the classic triad of obstructive 
symptoms : 
 difficulty initiating voiding,  
 fullness after voiding, and  
 increased post void residual urine volume  
characterizing diabetic cystopathy .Similarly, frequency and 
urgency are associated with both Diabetes-induced detrusor instability 
and benign prostatic hyperplasia. 
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        From patients with hypertrophy of prostate those with the higher 
levels of serum glucose (>110mg/dL) had a considerably higher mean 
prostate volume in comparison with patients with low levels of serum 
glucose. In patients with lower urinary tract symptoms , a further increase 
in prostate growth rate with the increasing levels of serum insulin was 
noticed. 
     Abnormalities of glucose homeostasis could play a role in the 
cause of BPH by influencing the proliferation rate of prostate cells. Thus, 
the study aims at identifying the correlation between duration and 
glycemic control of Diabetes and prevalence of prostatomegaly. 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
PRIMARY AIM: 
To study the prevalance of prostatomegaly and morphological 
charachteristics of prostate in patients with type 2 Diabetes Mellitus in 
comparison with non diabetic control.  
SECONDARY AIM: 
1. To study the effect of prostatomegaly and its complications with 
duration of type 2 Diabetes. 
2. To study the effect of prostatomegaly and its complications with 
glycemic control of type 2 Diabetes. 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
INTRODUCTION 
Diabetes includes a group of metabolic abnormalities showing 
phenotype of hyperglycaemia. This metabolic dysregulation leading to 
Diabetes also leads to secondary pathophysiological changes in multi 
organ systems, imposing an excessive burden on Patients with Diabetes 
and also towards health care system predisposing patients to 
cardiovascular disease. 
Factors contributing to hyperglycaemia: 
 Reduced insulin secretion 
 Decreased utilization of glucose 
 Increased production of glucose 1. 
Due to an increased incidence worldwide, Diabetes will soon 
become a leading cause of morbidly and mortality. 
CLASSIFICATION OF DIABETES 
Diabetes classified based on pathogenic process leading to 
hyperglycaemia in opposition to criteria such as age of onset, type of 
therapy which were used earlier. 
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ETIOLOGICAL CLASSIFICATION OF DIABETES 
TYPE 1 – results from a complete or total absence of insulin 
TYPE 2 – includes diverse  group of diseases involving: 
 Various levels  of resistance to insulin, 
 Insulin secretory impairment, 
 Excessive production of glucose. 
Abnormal homeostasis of glucose is usually seen prior to 
developing overt Diabetes. 
       Even though type 1 Diabetes occurs prior to the age 
30,autoimmune destructive process towards beta cell develops at any 
age.5-10 percent of patients developing Diabetes after age 30 is observed 
to have type 1 Diabetes Mellitus2. 
Type 2 Diabetes occurs mostly with increased age, in recent times 
being observed amongst young adults. 
MODY AND MONOGENIC DIABETES MELLITUS 
Involves autosomal dominant inheritance 
Delayed onset of hyperglycaemia (average of 25 years ) 
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GESTATIONAL DIABETES MELLITUS 
• Glucose intolerance during pregnancy 
• Due to resistance to insulin secondary to metabolic changes of late 
pregnancy 
• Increased requirement of insulin 
• Incidence – on an average 7 percent 
Most of whom revert to normal in the postpartum period (with a 
risk of 25- 50 percent for having Diabetes Mellitus in the following 10  
years). 
      IADP  STUDY GROUPS AND ADA  suggests once Diabetes is 
detected at an early prenatal screening  can be grouped  as overt Diabetes 
mellitus instead of  Gestational Diabetes Mellitus. Due to increasing 
incidence   of obesity, patients with gestational Diabetes mellitus/ overt 
Diabetes is on rise. 
EPIDEMIOLOGY AND GLOBAL CONSIDERATIONS 
Diabetic prevalence rose dramatically over the past two decades,   
from  around  32  million  patients  in 1987 to about 382 million  patients 
in 2014. With the prevailing data, the IDF suggests that 592 million 
person would have DIABETES by the year 2035. Eventhough  
  
prevalence of both the  types of 
diabetic patients tend to grow much rapidly due to prevailing obesity, 
decreased activity levels. 
The countries with highest count of patients  with DIABETES 
mellitus in 2014 are India (62.2 million), China (97.3 million), United 
nations (24.6 million), Brazil (12.1 million), and  Russia(11.9 million). In  
a recent study by  Center for Disease Control and Prevention (CDC) 
showed  that around 9.2% of the people  h
patients with Diabetes 
around 50% of patients  might be undiagnosed).  
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Diabetes are increasing globally, type 2 
 
as Diabetes 
are not diagnosed; worldwide, it is projected  that 
 
(~28% of the 
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The CDC 3 has shown an estimate of  prevalence  that has doubled 
from  year 1990–2008, but appeared  to have plateaued from year 2008–
2012. In 2013, type 2 Diabetes prevalence  in United Sates is  estimated 
to be 0.3% in patients  aged<25 years and around 12% in individuals 
aged >20 years. Globally  most of the individuals with Diabetes are 
within the age group of 40 and 59 years.  
There are  widespread geographic variations among the type 1 and 
type 2 Diabetes incidence.  Scandinavia records the highest number of 
cases of type1 Diabetes; with the lowest number of cases  in the Pacific 
Rim where it is around 20- to 25-fold lesser. This widespread variability 
is because of genetic, environmental and behavioural factors. 
       Prevelance of Diabetes varies amongst populations with different 
ethnicity inside a  given  country,  with  populations indigenous to the 
area having a greatest prevalence of type 2 Diabetes in comparison with 
the general population of that country.  
Among Asians ,prevalence of Diabetes is on  rising trend , and 
Diabetes phenotype appears to be varied from United states population, 
with onset at a younger age and a lower body mass index, reduced insulin 
secretory capacity and a greater visceral adiposity. 
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RISK FACTORS FOR TYPE 2 DIABETES 
  
  
  
SCREENING 
The Use of  FPG or HbA1c  as a screening test is 
type 2 DIABETES globally  as:
 a  large group of  individuals  meeting the current criterion for 
DIABETES are asymptomatic including those not aware that of  
having the disorder
 epidemiologic studies predicts that type 2 
present  up to more than a decade before proceeding to diagnosis, 
11 
 
recommended for 
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Diabetes 
 
might be 
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 some of the  individuals having type 2 Diabetes may be having  
more than one Diabetes-induced complications during  diagnosis,  
 Type  2 Diabetes treatment might alter the  history  of  Diabetes 
favourably,  diagnosis  of  these pre Diabetes helps in achieving a 
good prognosis.   
    ADA  recommends  screening  all  individuals who are >45 years 
once in every 3 years. It also recommends  screening  individuals at a 
much earlier age, in case of  patients being overweight (BMI >25 
kg/m2).In comparison with patients with type 2 Diabetes, a longer  
asymptomatic period of hyperglycemia is usually rare in patients having 
type 1 Diabetes prior to diagnosis.  
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REGULATION OF GLUCOSE HOMEOSTASIS 
       Glucose homeostasis is important in maintaining a balance between 
the hepatic production of glucose and the peripheral uptake and utilization 
of glucose. Insulin is an important regulator for this metabolic 
equilibrium, but metabolic signals, other hormones (glucagon) and neural 
input and resulting  in  integrated control of the supply and  the utilization 
of glucose.     
    Organs regulating glucose and lipids tend to communicate by 
various neural and the humoral mechanisms 6 producing myo-
kines,adipokines, and metabolites influencing liver function.  
During fasting, low insulin levels may increase  production of 
glucose by promoting glycogenolysis and gluconeogenesis  with   glucose 
uptake reduction in such  insulin-sensitive tissues such as skeletal muscle 
and the fat , hence promote mobilization of stored precursor form of  free 
fatty acids and amino acids . 
  
14 
 
Glucagon that is secreted by the  alpha cells of pancreas whenever 
blood glucose levels  or levels of insulin  are low, stimulating 
glycogenolysis and gluconeogenesis by renal medulla and liver . 
Following a meal, glucose load leads to rise in insulin with fall in 
glucagon which  leads to reversal of the above processes.   
Insulin, which is an anabolic hormone, promotescarbohydrate 
storage with   synthesis of protein and fat. A larger portion of  these 
postprandial glucose is utilised by skeletal muscle,  an insulin-stimulated 
glucose uptake mechanism. Other organs like brain, use glucose in the 
otherway, that is by an  insulin-independent mechanism. Growth Factors 
secreted by the myocytes (irisin), fat cells  (leptin, resis-tin, adiponectin) 
and bone may  influence homeostasis of glucose too 5. 
 
 
  
15 
 
  
INSULIN BIOSYNTHESIS 
Insulin produced by the beta cells in the islets of pancreas. 
Synthesis initially proceeds as a single-chain of  86-amino-acid precursor 
polypep-tide, preproinsulin. Further subsequent proteolytic processing 
aids in removing the amino-terminal signal peptide, thereby giving rise to 
the proinsulin.  
        
  
Proinsulin is related morphologically to insulin
I and II, that binds to insulin receptor we
cleavage of  31 residue fragment leading to the generation  of  C peptide 
with A  and B (30 chains of insulin, joined by disulfide bridges. 
       The above said molecules  are stored together ,on stimation are 
secreted from the pancreatic  beta
much slower than insulin, being used as a marker for secretion of insulin. 
This helps in differentiation  between exogenous and endogenous insulin 
during the  hypoglycaemia evaluation.  
16 
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Beta cells of pancreas also secrete amylin and islet amyloid 
polypeptide (IAPP) 9 together  with insulin. The function of IAPP is 
incompletely defined yet , but it is considered a prime component of  the 
amyloid fibrils present in pancreatic islets in  type 2 DIABETES patients. 
INSULIN SECRETION 
Glucose is the principle source of secretion of insulinby pancreatic 
beta cells, even though ketones, amino acids, various other  nutrients, 
gastro-intestinal peptides, key neurotransmitters may  also influence 
insulin secretion.  
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      Glucose levels >70 milligram/dL  stimulates synthesised insulin,  by 
enhancement of  translation of protein and processing. Glycemic  
stimulation of secretion of insulin is initiated by a facilitative glucose 
transporter into the beta cell of pancreas. 
INSULIN ACTION 
Once secretion of insulin occurs in to the portal venous system, 
nearly 55% is being taken up and thereby destroyed by  the liver. 
Unextracted insulin entering systemic circulation leads to  binding  of 
insulin to  receptors present in target sites. This process  leads to  
stimulation of  intrinsic tyrosine kinase activity,  ultimately resulting  in 
autophosphorylation of receptor  and intracellular signaling molecule 
recruitment, like that of  insulin receptor substrates (IRS). 
Insulin receptor substrates (IRS)  initiates a  complex series  of 
phosphorylation and dephosphorylation 8 reactions, leading to  a enhanced 
metabolic  changes and  mitogenic  actions  of  insulin. 
Phosphatidylinositol-3′-kinase (PI-3-kinase) pathway stimulation causes 
movement of  glucose  transporter  (e.g.,  GLUT4)  to the cell surface, 
playing  a key role  for uptake of glucose by myocytes  and  adipocytes.    
Insulin  receptor  stimulation induces signaling  pathways thereby induces  
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synthesis of glycogen, protein and fat and regulation of many other genes 
in cells that are responsive to insulin  
 
PATHOGENESIS OF TYPE 2  DIABETES 
Resistance to insulin and an reduced secretion of  insulin are 
primary to the pathogenic development of type 2 Diabetes. Resistance to 
insulin usually precede an secretion of insulindefect  but, development of 
Diabetes occurs only in situations where secretion of insulin reaches to a 
state of inadequacy. It has become  increasingly  apparent that Diabetes 
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has a different pathophysiological process in different ethnic groups 
(Asian, African, and Latin American).  
 
GENETIC  CONSIDERATIONS 
       Type 2 Diabetes have a stronger genetic predisposition. Type 2 
Diabetes concordance among identical 12twins is about 72 to 88%. 
Individuals with type 2 diabetic parent  acquire an much higher tendency 
to develop  Diabetes; in case of type 2 Diabetes in both the parents,  the  
risk  reaches upto 38%.   
  
21 
 
       Resistance to insulin, as evidenced by decreased utilization of glucose 
in peripheral myocytes, is also seen in  nondiabetic, first-degree relatives 
of patients  with type 2 Diabetes. The disease is multifactorial  and also 
polygenic , consisting of  genetic susceptibility, other environmental 
factors (such as obesity, dietary habits  and physical inactivity) leads to 
phenotype modulation.  
 The in utero milieu  of the foetus  contributes , which can be either 
an  increased or decreased birth weight leading to increase  in the risk of 
type 2 Diabetes in adult life. The genes11 that are predisposing to type 2 
Diabetes are yet not completely defined, but more genome-wide 
association  studies  had  discovered  a  much higher count  of genes 
which convey a lesser  tendency for type 2 Diabetes.  
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        Major  prominent feature is a variant of transcription factor 7–like 2 
gene that is found to be linked with type 2 Diabetes in many individuals. 
The mechanism of genetic predisposition is likely to be alteration in the 
islet cell development or function, resulting in change of insulin secretion. 
PATHOPHYSIOLOGY 
Type 2 Diabetes is generally characterized by impairment of  
insulin secretion, resistance to insulin, increased production of glucose by 
the liver, and an altered adipose tissue  metabolism. Obesity, especially  
visceral or central (as measured by the hip-waist ratio), is much more 
prevalent in type 2 Diabetes (≥75% of individuals  are obese). 
In the earlier stages of  disorder, glucose tolerance  comes to near 
normal,  even in the presence of  insulin  resistance,  as  the  pancreatic  
beta  cells  tends to compensate  by  improving the insulin  output .  As 
the resistance to insulin and a compensatory raise in insulin progresses, 
the islets of pancreas are not able to maintain the hyperinsulinemic13 
scenario. Impairment in  glucose tolerance, that is characterized by a rise 
in postmeal glucose,  thus develops.  
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A decline  in secretion of insulin and an increment in glucose 
production by the liver thus leads  to overt Diabetes along with fasting 
rise in glucose. Ultimately leading to failure of beta cells .Although both 
the resistance to insulin and impairment in secretion contributes  to the 
underlying pathogenesis of type 2 Diabetes, the relative contribution of 
each of them varies among individuals. 
METABOLIC ABNORMALITIES   
ABNORMAL MUSCLE AND FAT METABOLISM 
      Resistance to insulin, leading to the reduced ability of insulin to 
function effectively on the target cells (especially on myocytes, 
heptocytes and adipocytes), is thus a prime feature of type 2 DIABETES 
and resulting  from  combination of genetic susceptibility and obesity.  
Resistance to insulin is however relative, because increased  
circulating insulin levels will tend to normalize the serum  glucose 
concenteration. Shift of insulin dose response curves to the rightward axis, 
thereby,  indicating 15 decreased sensitivity, and low maximal response, 
thus leading to  an overall decrement  in maximual utilization of glucose.  
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Resistance to insulin leads to impairment of utilization of glucose 
by the peripheral tissues resulting in a further increase in glucose output 
by the liver leading to a vicious cycle ;  both effects contributing to the 
resulting hyperglycemia. Increment in glucose output by liver  
significantly  causes raised  Fasting plasma glucose  levels, whereas 
reduced  l glucose utilisation  results in postmeal raised serum glucose.  
           In myocytes, there is higher impairment  in nonoxidative utilisation 
of glucose than in oxidative glucose metabolism through the mechanism 
of  glycolysis. Metabolism of glucose that occurs in insulin-independent 
tissues is not changed in type 2 Diabetes.  
Levels of Insulin receptors and  tyrosine kinase activity in 
myocytes are decreased, but these changes  tends to be  mostly due  to 
hyperinsulinemia and aren’t due to a  basic defect. Therefore, these 
“postreceptor” defects that occurs in insulin dependent  phosphorylation 
/dephosphorylation process appears  to play a pivotal  role in the 
resistance to insulin.  
Alterations  includes the  lipid accumulation within  myocytes, 
which might  impair the oxidative phosphorylation in mitochondria and 
reduces  insulin dependent mitochondrial production of ATP. Impairment 
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in  oxidation of fat and storage of lipids within  muscle  also  might 
release free radicles such as lipid peroxides 14.  
 
As a result, raised insulin levels  can  escalate the effects of  insulin, 
thereby stimulating  atherosclerotic changes in the vessel wall. Visceral or 
central obesity, is a  part of  this pathogenic process . Brown fats have a 
greater advantage as having thermogenic capcity compared to these white 
fat depots.  
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Obesity, in turn stimulates the synthesis and release of many 
enzymes and hormones (leptin, adipokines, retinol binding protein, 
Interleukin 6 , resistin and tumour necrosis factor alpha ). These factors 
play a key role in the appetite stimulation , regulation of body weight , 
expenditure of energy and modulation of insulin sensitivity in the 
peripheral tissues.however, certain adipokines and free fatty acids  leads 
to insulin resistance in myocytes and hepatocytes. 
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INFLAMMATORY CASCADE STIMULATED BY INSULIN 
 
       Production of excess free fatty acids in patients with obesity not 
only results in impairment of glucose by the peripheral tissues, but also 
causes excess production and releases of glucose from the liver with 
impairing the function of pancreatic beta cells 15. In contrast to the 
scenario, releases of adiponection from the adipocytes, which is a insulin 
sensitizing peptide is much lowered in obese patients thereby, 
contributing to the elevated insulin resistance. 
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PHYSIOLOGY OF GLUCOSE COUNTER-REGULATION 
 
The products of adipocytes  namely, adipokines leads to induction 
of  an inflammatory state and  excess production of Interleukin 6 and C-
reactive protein with the infiltration of  inflammatory cells  within the 
adipose tissue. Experiments in animal  and human models has revealed 
that on inhibiting inflammatory signalling pathways namely nucler factor 
–kappa B16 results in reduction of insulin resistance with improvement in 
hyperglycemia. 
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       Secretion of insulin and its sensitivity in the peripheral tissues are  
interrelated. In patients with  type 2 Diabetes, eventhough, the function of 
pancreatic beta cells appears to be lowered by 50% ,defect in insulin 
secretion is only very mild and tends to maintain the normal secretion in 
response to glucose and other insulin secretogogues like arginine. 
Studies indicate that overlapping with the insulin resistance , a 
second genetic defect results in failure of pancreatic beta cells and 
reduction of beta cell mass by around 50%. In patients with chronic 
diabete mellitus, amylin or islet amyloid polypeptide that is secreted along 
with the insulin gets deposited in the islets forming amyloid fibrillar 
deposits.  
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        In patients with longstanding Diabetes , chronic hyperglycemia has a 
negative impact on function of islet cells (glucose toxicity),leading to 
deterioration of Diabetes. Well controlled Diabetes has  a positive effect 
on islet cell function. Excess dietary fat and free fatty acids (lipotoxicity) 
also worsens function of islet cells. 
GLP 117 acts by increasing the secretion of insulin and reduction in 
glucose output by the liver, decrease in lipid production. Due to resistance 
of insulin in the adipocytes, lysis of lipids and release of excess of free 
fatty acids occur with the increment in low density lipoprotein and 
triglycerides.  
          Excess steatosis in the hepatocytes  results in development of non-
alcoholic steatohepatitis (NASH) with abnormality in liver function tests. 
The above process results in dyslipidemis with elevation in triglyceride 
and low density lipoprotein levels with decrement in high density 
lipoprotein. This insulin resistance results in a group of metabolic 
derangements such as central or visceral obesity, hypertension , 
dyslipidemia and an increased risk for cardiovascular events. Acanthosis 
nigricans and features of hyperandrogenism (acne , hirsutism and 
oligomenorrhoea )18, poly cystic ovarian syndrome  may predominate. 
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Among adults, two forms of insulin resistance persists:  
(1) type  A, affecting  young females with features of 
hyperandrogenism (acne , hirsutism and oligomenorrhoea; and obesity 
 (2) type B  involves  middle-aged females that has characteristics 
of  severe hyperinsulinemia,  hyperandrogenism features  and 
autoimmune conditions. 
Type B syndrome involves production of auto antibodies against 
insulin receptor, which might block the binding of insulin resulting in 
hyperglycemia or causes excessive stimulation of receptor leading to 
intermittent hypoglycaemia. 
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MANAGEMENT OF TYPR 2 DIABETES 
The major components in the treatment of type 2 DIABETESincludes: 
        -Lifestyle modifications 
        -Pharmacotherapy 
 Oral hypoglycaemic agents 
 Antihyperglycemic agents 
 Injectable agents (Insulin) 1 
         -Treatment of complications 
         -Treatment of associated conditions (hypertension / dyslipidemia) 
ESSENTIAL COMPONENTS OF MANAGEMENT OF  
TYPE 2 DIABETES 
 
  
33 
 
LIFESTYLE CHANGES 
DIET CONTROL 
      Dietary approach and meal plan in DIABETES plays an pivotal role in 
control of hyperglycemia and to overcome the peripheral tissue resistance 
to insulin, also helps in prevention of further end organ damage and for 
the control of associated comorbid conditions. 
-food containing excess of vegetables should be encouraged 
-food containing fat and excess carbohydrate should be avoided 
- fruits containing dietary sucrose (mangoes,banana,jackfruit ) 
should be exempted from diet 
-vegetables which are cultivated from underground should be 
avoided (excepting groundnut). 
EXERCISE 
 Daily aerobic exercise (brisk walking, gym, treadmill) lasting for 
around 20 minutes is essential for atleast 5 days a week. It effectively 
helps by increasing secretion of insulin with reduction of peripheral 
resistance. 
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PHARMACOTHERAPY
Treatment of 
antihyperglycemic agents by acting on peripheral 
resistance to insulin , acting by reducing gluconeogenesis
Metformin is the most commonly preferred drug among all the oral 
hypoglycaemic agents, due to its superior efficacy and potency.
35 
 
 
Diabetes with either oral hypoglycaemic agents, 
tissues to reduce 
 
20.
 
 
 
  
 
36 
 
 
  
37 
 
SULFONYLUREA 
         Acts by the mechanism of closure of ATP mediated K channels, 
which in turn leads to cellular depolarisation causing opening of calcium 
channels leading to release of Insulin. Thus, it has the disadvantage of 
producing hypoglycaemia in case the patient takes the drug without the 
intake of meals. 
 
INJECTABLE INSULIN PREPARATIONS  
These are being more widely used for those patients who have 
uncontrolled Diabetes even while on treatment of oral hypoglycaemic 
agents, microvascular or macrovascular complications. 
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VARIOUS FORMS OF INSULIN PREPARATIONS 
 
TIMING AND TYPE OF INSULIN ADIABETESINISTRATION 
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A. Timing of insulin administration varies between each individual 
and it is an patient tailored approach. In the above diagram, regular 
/ short acting insulin is administered as three doses per day before 
breakfast, lunch and dinner and a long acting basal insulin  once a 
day.  
B. The diagram depicts the insulin Administration as a dual rapidly 
acting dosage, dual intermediately acting insulin. 
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C. The diagram shows that insulin is given as a single basal 
formulation with  multiple bolus injection before each meal21.  
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COMPLICATIONS OF DIABETES 
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Since progression of DIABETES ( uncontrolled / chronicity ) is 
associated with multiple microvascular and macrovascular complications , 
resulting in early morbidity and mortality. 
 
       The mainstay of  primary treatment aims at prevention of  vascular 
complications, in case of occurrence of complications secondary 
treatment should be aimed at treating the disease and preventing it from 
further progression , thereby decreasing the mortality and morbidity. 
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BENIGN PROSTATIC HYPERPLASIA (BPH)  
INTRODUCTION 
      Benign prostatic hyperplasia (BPH), charachterised by an increase in 
size and number of cellular elements of prostatic tissues is an diagnosis 
made histologically. 
 
Longstanding bladder outlet obstruction (BOO) due to Benign 
prostatic hyperplasia might  result  in  retention of urine, recurrent urinary 
tract infections, renal insufficiency  and stone in bladder16.  
Benign prostatic hyperplasia  primarily involving the  epithelial and 
stromal components of prostate that is present in the periurethral and 
transition zone leads on to restriction of urinary flow . The basic 
underlying pathogenesis would be excess proliferation of stromal and 
epithelial cells or impairment of programmed cell death (apoptosis). 
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Since, benign prostatic hyperplasia is primarily dependent on 
testosterone and dihydrotestosterone, it is projected as a part of aging 
process. Approximately, about 53% of males evidence histopathologic 
Benign prostatic hyperplasia  by the age of  60 years. This figure  further 
increases to about 90% by the age of 85 years.  
   The voiding dysfunction that is resulting from bladder outlet 
obstruction (BOO) is named as  lower urinary tract symptoms (LUTS) or 
as prostatism . These entities tends to overlap; that not all males with 
LUTS have BPH and that not all the males with BPH have LUTS22. 
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Approximately around 50% of  males being detected with 
histopathologic evidence of benign prostatic hyperplasia  are found to 
exhibit moderate-to-severe LUTS.  
FUNCTIONS OF PROSTATE GLAND 
The major role of prostate gland is to synthesize and secrete an 
alkaline fluid that includes constituting around 70% of the volume of 
semen. They aid in lubrication and nourishment for the sperm , helps 
liquefaction of seminal plug and in neutralizing  the acidic nature of  
vaginal environment. 
    The prostatic urethra acts as a pathway for passage of  semen and 
controls retrograde by blocking the bldder neck at the time of sexual 
climax.  Ejaculation tend to  involve a coordinated action of various tissue 
components, including vasa deferentia, smooth muscles of seminal 
vesicles, the ischiocavernosus and bulbocavernosus muscles and the 
ejaculatory ducts. 
PATHOPHYSIOLOGY OF BPH 
       Enlargement of prostate primarily depend on the most potent 
androgen dihydrotestosterone (DHT). In the prostate gland, type II 5-
alpha-reductase tends to metabolize circulating testosterone into its 
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metabolically active product DHT, which work over local tissues, not 
systemically. DHT act by binding to androgen receptors in the cellular  
nucleus, lading on to benign prostatic hyperplasia. 
 
 Numerous studies had projected that huge  number of alpha-1-
adrenergic receptors are  present in  stromal and capsular smooth muscles 
of the prostate, and  in the neck of bladder. Stimulation of these receptors 
cause an increment in tone of smooth-muscles , that  tend to  worsen 
lower urinary tract symptoms15. Conversely, receptor blockade tends to 
loosen the  muscles, with subsequent LUT symptom relief. 
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Microscopically, BPH is characterized by a hyperplastic process. 
The hyperplasia thus results in enlargement of the prostate gland  that 
might restrict the urinary flow  from the bladder, resulting in clinical 
symptoms of BPH. The prostate gland  enlarges with age in a hormonally 
dependent manner. Thus, castrated males (who are  not able to make 
testosterone) do not develop BPH. 
The knowledge  behind Benign prostatic hyperplasia is that, as the 
gland enlarges in size, the overlying  capsule tends to prevent  it from 
expanding radially, leading on to  urethral compression and LUTS. 
However,bladder dysfunction due to obstruction contribute predominantly 
to LUTS. The bladder wall become much trabeculated,  thickened, and 
irritable on forcing it to hypertrophy and increases its own contractile 
power. 
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Urinary frequency and symptoms of lower urinary tract are 
secondary to increase in sensitivity (detrusor overactivity) of the 
myocytes. Bladder might weaken gradually and loses its ability to 
completely empty, leading to higher amount of residual urine and, 
possibly, to bacterial infection, acute or chronic urinary retention. 
       This tends to become a vicious cycle with obstruction leading on to 
hypertrophied smooth muscles. Specimens of trabeculated bladder 
demonstrates evidence of few myocytes with an increment in collagen 
content. The collagen fibres limits its compliance, leading to higher 
amount of bladder pressure upon filling.  
EPIDEMIOLOGY 
Benign prostatic hyperplasia is a widespread condition  that affects 
the quality of life significantly in approximately 30% of males above  50 
years. Benign prostatic hyperplasia  is found to be histologically evident 
in around 88% of men by age 80 years. Globally, around 28 million males 
are likely to  have symptoms secondary  to Benign prostatic hyperplasia 
The prevalence of Benign prostatic hyperplasia in whites and 
American-african males are the same14 . However, BPH has a severe and 
a progressive course in American-african males, due to the higher levels  
of testosterone, 5-alpha-reductase activity, expression of androgen 
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receptors, and activity of growth factor in this group of  population. This  
increment in  activity leads      to an further  higher  rate of hyperplastic 
proatate and its complicating sequelae. 
 
CLINICAL MANIFESTATIONS 
Signs and symptoms 
With enlargement of prostate, it tends to constrict the urinary flow. 
Nervous system present inside the prostate and bladder might also be a 
factor involved in causing the symptoms. 
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The symptoms of benign prostatic hyperplasia includes difficulty in 
initiation of urinary stream along with difficulty in maintaining the 
stream, frequent passage of urine  at night secondary to retention of urine 
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(post void residual urine),  dribbling of urine , secondary bacterial 
infections  and loss of libido. 
 
DIAGNOSIS 
DIGITAL PER-RECTAL EXAMINATION 
        It the major test aiding in evaluation of patients with BPH, helps in 
assessing the contour, size, consistency , texture of the prostate , 
evaluation of nodules if present, where areas of malignancy can be 
detected. 
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LABORATORY STUDIES 
URINE ANALYSIS  
        Examination of centrifuged sediment urine with the help of dipstick 
methods aids in identification of presence of blood , bacteria , protein , 
leukocytes or glucose. 
Urine culture  
       In case the urine analysis predicts an abnormality, infectious cause 
of irritative voiding needs to be excluded. 
PROSTATE-SPECIFIC ANTIGEN  
Benign prostatic hyperplasia is not routinely associated with 
malignancy, but however they tend to carry a higher risk compared to a 
general population. Thus, screening routinely is a prerequisite. 
Electrolytes, Blood Urea Nitrogen (Bun), And Creatinine  
Helpful in patients with chronic renal disease  who had  large 
amounts  of postvoid residual (PVR) urine volume.   
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ULTRASONOGRAPHY 
       Ultrasonography is a helpful tool  in order to assess bladder and 
prostate size  and presence of  hydronephrosis (if present ) in males  with 
retention of urine and symptoms or signs of kidney disease. 
 Generally in the evaluation of uncomplicated LUTS, 
ultrasonography is not routinely indicated. Done in the radiology 
department by a senior radiologist using 3.5 MW Mechanical Probe USG 
machine for  various radiological diagnostic conditions causing prostatic 
hypertrophy (such as BPH, prostatic abscess, prostatitis) with special 
importance aimed at radiological grading of prostatomegaly,  
pyelonephritis  [presence of particulate matter in the collecting system, 
appearance of decreased vascularity in cortex  , presence of air bubbles 
(emphysematous pyelonephritis), abnormal renal parenchymal 
echogenecity, cystitis [thickened  bladder wall as a result of wall edema] 
and estimating the amount  of residual urine12. 
LOWER URINARY TRACT  ENDOSCOPY  
Cystoscopy might  be useful in males who are posted for invasive 
treatment or in patients to whom we are suspecting the presence of  
foreign body or malignancy.  Endoscopymis useful  in patients with a 
  
prior sexually transmitted disease (eg, gonococcal urethritis) history ,  
history of prolonged  urinary catheterization, or presence of  trauma.
IPSS/AUA-SI 
The grade of  BPH is assessed using  INTERNATIONAL 
PROSTATE SYMPTOM SCORE (IPSS)/AMERICAN UROLOGICAL 
ASSOCIATION SYMPTOM INDEX (AUA
quality of life (QOL) question. 
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-SI)  with  a disease
 
 
-specific 
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UROFLOWMETRY 
Flow rate  
        Turns out to be helpful to assess the response to treatment. 
PVR urine volume  
        Useful in gauging  the bladder decompensation severity and also be 
obtained invasively with  catheter or sometimes, noninvasively with a 
transpelvic ultrasonic scanner18. 
Pressure flow studies  
         Results  might be  useful in evaluation of outlet obstruction of 
bladder. 
Urodynamic flow studies      
       Helps in distinguishing  poorer bladder contractility  (decreased 
detrusor activity) from outlet obstruction of bladder. 
CYTOLOGIC EXAMINATION OF THE URINE  
       Used in those patients with irrittive symptoms. 
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MANAGEMENT 
Pharmacotherapy 
      Agents that are used in the treatment of BPH includes the following: 
 Alpha-adrenergic receptor blockers 
 Alpha-1–receptor blockers 
 Phosphodiesterase-5 enzyme inhibitors 
 5-alpha reductase inhibitors 
 Anticholinergic agents 
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SURGERY 
Transurethral resection of the prostate (TURP)  
       The standard procedure to relieve bladder outlet obstruction that 
occurs  due to BPH. 
Open prostatectomy  
Usually reserved for:  
 males with  a prostates size  of >75 g.,  
 males with associated  bladder stones or diverticulum of bladder   
 males who cannot tolerate or position for transurethral surgery 
Minimally invasive treatment 
1.Transurethral incision of the prostate (TUIP) 
2.Laser treatment – helps in  cutting or destroying the  prostatic tissues. 
3.Transurethral microwave therapy (TUMT)  
Acts by producing heat that destroys the prostatic cells , resulting in 
shrinkage and reduction in prostatic volume. 
4.Transurethral needle ablation of the prostate (TUNA) 
5.High-intensity ultrasonographic energy therapy  
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6.Prostatic stents  
      These are Flexible devices that tends to dilate  once placed in position 
to improve the .urinary flow rate. 
7.Laparoscopic  procedures (prostatectomy). 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Study Centre  
   Department of Diabetology and Institute of Internal medicine, 
   Madras medical college,  
   Rajiv Gandhi government general hospital, 
   Chennai-3. 
 
Duration of Study   
6 months 
 
Study Design 
Observational Study ( prospective and retrospective ) 
 
Sample Size 
100 patients 
 
Inclusion Criteria 
Patients with Type 2 Dibetes mellitus aged 40- 60 years. 
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Exclusion Criteria 
1.Known case of : 
       -BENIGN PROSTATIC HYPERPLSIA 
       -CARCINOMA PROSTATE 
2.Age > 60 years 
Data Collection and Methods 
Type 2 diabetic  patients  attending  Diabetology OP of RGGGH 
and inpatients of Institute of Internal Medicine are subjected to detailed 
history taking , clinical examination and required investigations. 
Materials and Methods 
• From Type 2 Diabetes patients getting Admitted in Medicine ward/ 
attending the Diabetology department OPD, selected for clinical 
study as per inclusion/exclusion criteria the following data are 
collected: 
                 -Demographic data  
                 -Medical history 
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• Patients are subjected to: 
                 -Blood sugar estimation (fasting /postprandial) 
                 -HbA1c 
                 -Serum Prostate Specific Antigen(PSA) 
                  {for selected patients} 
                 -Ultasound pelvis.  
Analysis Plan 
SPSS, Epi INFO softwares 
Sponsorship  
No  
Conflict of interest 
None 
OBSERVATIONS AND RESULTS  
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OBSERVATION AND RESULTS 
FLOW CHART OF THE METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL NUMBER 
OF CASES =100 
APPLYING THE 
INCLUSION AND 
EXCLUSION 
CRITERIA 
    COLLECTING 
RELEVANT DATA  
SUBJECTING TO  
INVESTIGATIONS 
    FBS /PPBS 
    HBA1c 
    SERUM PSA 
    USG PELVIS 
   
CORRELATING PRESENCE OF 
PROSTATOMEGALY WITH 
GLYCEMIC PROFILE AND 
DURATION OF DIABETES 
  
60%
FREQUENCY OF AGE WISE
 
From the above table,it is evident that around 40% patients fall 
within 40-50 years of age and about 60% patients fall within 50
of age. 
PIE CHART SHOWING  AGEWISE DISTRIBUTION IN OUR 
 
 
 
 
 
 
 
AGE_GROUP
40-50 years
51-60 years
Total
63 
40%
 DISTRIBUTION IN OUR STUDY 
GROUP 
STUDY GROUP 
 FREQUENCY 
 40 
 60 
 100 
40-50 years
51-60 years
-60 years 
PERCENT 
40.0 
60.0 
100.0 
  
FREQUENCY OF PRESENCE OF LUTS SYMPTOMS IN OUR 
LUTS SYMPTOMS
NO 
YES 
Total 
 
In  our study 
around 27% of patients had symptoms that are attributable to lower 
urinary tract. 
 
 
FREQUENCY OF PRESENCE OF LUTS 
SYMPTOMS IN OUR STUDY POPULATION 
64 
STUDY POPULATION 
 FREQUENCY PERCENT
73 
27 
100 
group, out of the total population with prostatomegaly 
73%
27%
 
73.0 
27.0 
100.0 
 
NO
YES
  
PERCENTAGE  OF PATIENTS IN OUR STUDY GROUP 
HAVING HYPERTENSION ALONG WITH DIABETES
HYPERTENSION
NO 
YES 
Total 
 
The above table depicts that among 100 patients with type 2 
Diabetes, around 28% patients had coexistent hypertension.
 
PERCENTAGE  OF PATIENTS IN OUR STUDY 
GROUP HAVING HYPERTENSION ALONG 
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 FREQUENCY 
72 
28 
100 
 
72%
28%
WITH DIABETES
 
PERCENT 
72.0 
28.0 
100.0 
 
 
NO
YES
  
FREQUENCY OF DYSLIPIDEMIA IN PATIENTS WITH 
DYSLIPIDEMIA
NO 
YES 
Total 
 
In our study group, among  100 patients with type 2  
about 22% patients had dyslipidemia.
FREQUENCY OF DYSLIPIDEMIA IN PATIENTS 
WITH DIABETES IN OUR STUDY
66 
DIABETES IN OUR STUDY 
 FREQUENCY 
78 
22 
100 
 
78%
22%
PERCENT 
78.0 
22.0 
100.0 
Diabetes 
 
NO
YES
  
PERCENTAGE OF PATIENTS ON OHA / INSULIN FOR THE 
DIABETES MANAGEMENT IN OUR STUDY POPULATION
TREATMENT
INSULIN 
OHA 
Total 
 
It is evident from the above table that around 70 % patients are on 
OHA and 30% patients on Insulin.From the other studies,it was predicted 
that more the number of patients on insulin for uncontrollable 
hyperglycaemia, more the incidence of prostatomegaly.
 
69%
PERCENTAGE OF PATIENTS ON OHA / 
INSULIN FOR THE DIABETES 
67 
 FREQUENCY 
31 
69 
100 
 
31%
MANAGEMENT
 
PERCENT 
31.0 
69.0 
100.0 
 
NO
YES
  
TABLE SHOWING TREATMENT REGULARITY IN PATIENTS 
TREATMENT 
REGULARITY
IRREGULAR
REGULAR
Total 
 
Around 86 % patients are on regular treatment, remaining 14% on 
irregular treatment for their 
 
PIE CHART SHOWING TREATMENT 
REGULARITY IN PATIENTS WITH DM
68 
WITH DIABETES 
 
FREQUENCY 
 14 
 86 
100 
Diabetes. 
14%
86%
PERCENT 
14.0 
86.0 
100.0 
 
IRREGULAR
REGULAR
  
FREQUENCY OF PATIENTS IDENTIFIED ON PER RECTAL 
EXAMINATION TO HAVE PROSTATOMEGALY
IDENTIFICATION OF 
PROSTATOMEGALY 
ON PR 
NO 
YES 
Total 
 
From the given table, it would be suggested that around 13 % 
patients could be identified to have prostatomegaly on per rectal 
examination. 
 
FREQUENCY OF PATIENTS IDENTIFIED ON 
PER RECTAL EXAMINATION TO HAVE 
69 
FREQUENCY 
87 
13 
100 
87%
13%
PROSTATOMEGALY
 
PERCENT 
87.0 
13.0 
100.0 
 
NO
YES
  
TABLE DEPICTING NATURE OF GLYCEMIC PROFILE IN 
GLYCEMIC 
PROFILE 
POOR CONTROL
GOOD CONTROL
Total 
 
It is obvious from the above table that around 52%  patients had 
poor glycemic control.
 
 
 
48%
PIE CHART DEPICTING NATURE OF GLYCEMIC 
70 
OUR STUDY 
FREQUENCY 
 52 
 48 
100 
 
52%
PROFILE 
PERCENT 
52.0 
48.0 
100.0 
 
ABNORMAL
NORMAL
  
TABLE DEPICTING DISTRIBUTION OF PATIENTS BASED ON 
HBA1C 
<7 
7-8 
8-10 
Total 
 
From the above table, it is evident clearly that around 50% patients 
have well controlled 
poorly controlled Diabetes 
 
PIE CHART DEPICTING DISTRIBUTION OF 
71 
HBA1C 
FREQUENCY PERCENT
52 
22 
26 
100 100.0
Diabetes, in comparison to 48% patients who have a 
over a period of 3 months duration.
52%
22%
26%
PATIENTS BASED ON HBA1C
 
52.0 
22.0 
26.0 
 
 
 
<7
7 to 8
8 to 10
  
PERCENTAGE OF PATIENTS WITH PROSTATOMEGALY IN 
PROSTATOMEGLY
NO 
YES 
Total 
 
Above table gives an idea  that around 50% patients in our study 
group had prostatomegaly.
 
51%
PERCENTAGE OF PATIENTS WITH 
72 
OUR STUDY 
 FREQUENCY 
49 
51 
100 
 
49%
PROSTATOMEGALY
PERCENT 
49.0 
51.0 
100.0 
 
NO
YES
  
FREQUENCY OF 
SPECIFIC ANTIGEN WAS TESTED
SERUM PSA 
 
<4ng/ml 
Total 
 
In our study, out of 100 patients serum prostrate specific antigen 
was only tested to those patients who for whom 
present and it came to around 51% .For all the 51 patients, level of serum 
prostrate specific antigen was <4 ng/ml.
51%
FREQUENCY OF PATIENTS FOR WHOM 
SERUM PROSTRATE SPECIFIC ANTIGEN WAS 
73 
PATIENTS FOR WHOM SERUM PROSTRATE 
 
FREQUENCY PERCENT
49 
51 
100 
prostatomegaly was 
 
49%
TESTED
 
49.0 
51.0 
100.0 
 
<4
  
TABLE SHOWING DISTRIBUTION OF PATIENTS BASED ON
DURATION OF 
DIABETES 
<5 years 
5  -10 years 
10-20years 
Total 
 
From the given table,it is depicted that 48% of our patients had 
Diabetes for a period of <5 years,15 % patients had 
5-10 years, with the remaining population having 
of 10- 20 years. 
37%
DISTRIBUTION OF PATIENTS BASED ON
74 
DURATION OF DIABETES 
FREQUENCY PERCENT
48 
15 
37 
100 
Diabetes 
Diabetes 
48%
15%
DURATION OF DM
 
 
48.0 
15.0 
37.0 
100.0 
for about  
for a duration 
 
1
2
3
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TABLE DEPICTING RELATIONSHIP BETWEEN DURATION 
OF DIABETES AND PRESENCE OF PROSTATOMEGALY 
CROSSTAB 
DURATION OF DIABETES 
Total 
1-5 years 6-10 years 
above 10 
years 
Prostato
megly 
NO 
Count 38 6 5 49 
% within 
PROSTATOMEG
LY 
77.6% 12.2% 10.2% 100.0% 
YES 
Count 10 9 32 51 
% within 
PROSTATOMEG
LY 
19.6% 17.6% 62.7% 100.0% 
Total 
Count 48 15 37 100 
% within 
PROSTATOMEG
LY 
48.0% 15.0% 37.0% 100.0% 
Chi-Square=36.611**P<0.001 
From the given cross tabulation ,it is evident that as the duration of 
Diabetes increases, size of prostrate gland also increases. 
There is a strong correlation between duration of Diabetes mellitus 
and prostatomegaly, as the p value is <0.001 which is considered as 
significant. 
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BAR DIAGRAM SHOWING CORRELATION BETWEEN 
DURATION OF DIABETES AND PROSTATOMEGALY 
 
  
77.60%
12.20%
10.20%
19.60%
17.60%
62.70%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
1-5 YEARS 6-10 YEARS ABOVE 10 YEARS
NO
YES
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TABLE DEPICTING RELATIONSHIP BETWEEN CONTROL  
OF DIABETES AND PRESENCE OF PROSTATOMEGALY 
CROSSTAB 
HBA1C 
Total 
<7 7-8 8-10 
Prostatomeg
ly 
NO 
Count 35 8 6 49 
% within 
PROSTATOMEGL
Y 
71.4% 16.3% 12.2% 100.0% 
YES 
Count 17 14 20 51 
% within 
PROSTATOMEGL
Y 
33.3% 27.5% 39.2% 100.0% 
Total 
Count 52 22 26 100 
% within 
PROSTATOMEGL
Y 
52.0% 22.0% 26.0% 100.0% 
Chi-Square=15.372**P<0.001 
In our study,it is evidenced that those patients who had DIABETES 
of poorer control over a period of time has increasing number of 
prostatomegaly . Similarly, there is very less number of patients with 
prostatomegaly in those who have strict control of DIABETES. 
It is found to be correlating significantly as the p value is < 0.001. 
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BAR DIAGRAM DEPICTING RELATIONSHIP BETWEEN 
CONTROL  OF DIABETES AND PRESENCE OF 
PROSTATOMEGALY 
 
71.40%
16.30%
12.20%
33.30%
27.50%
39.20%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
<7 7 - 8% 8-10%
NO
YES
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TABLE SHOWING PERCENTAGE OF PATIENT 
DISTRIBUTION BASED ON THE TREATMENT FOR DIABETES 
(OHA /INSULIN) 
CROSSTAB 
TREATMENT 
Total INSUL
IN OHA 
Prostato
megaly 
NO 
Count 0 49 49 
% within 
PROSTATOMEGALY 0.0% 100.0% 100.0% 
YES 
Count 31 20 51 
% within 
PROSTATOMEGALY 60.8% 39.2% 100.0% 
Total 
Count 31 69 100 
% within 
PROSTATOMEGALY 
31.0% 69.0% 100.0% 
Chi-Square=43.166**P<0.001 
The above table clearly depicts that those patients on Insulin has a 
higher incidence of prostatomegaly,in comparison to patients who were 
on oral hypoglycaemic agents. It is found to be correlating significantly 
as the p value is < 0.001. 
  
  
BAR DIAGRAM SHOWING PER
DISTRIBUTION BASED ON THE TREATMENT FOR DIABETES 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
INSULIN
80 
CENTAGE OF PATIENT 
(OHA /INSULIN) 
 
OHA
0%
61%
100%
39%
 
YES
NO
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TABLE SHOWING PERCENTAGE OF PATIENTS IDENTIFIED 
ON PERRECTAL EXAMINATION AS HAVING 
PROSTATOMEGALY 
CROSSTAB PR Total NO YES 
Prostatome
galy 
NO 
Count 49 0 49 
% within 
PROSTATOMEGALY 100.0% 0.0% 100.0% 
YES 
Count 38 13 51 
% within 
PROSTATOMEGALY 74.5% 25.5% 100.0% 
Total 
Count 87 13 100 
% within 
PROSTATOMEGALY 87.0% 13.0% 100.0% 
Chi-Square=14.357**P<0.001 
It has been evident from the above table, among patients having 
prostatomegaly about 25% patients are identified by per rectal 
examination. It is found to be correlating significantly as the p value is < 
0.001. 
 
 
 
 
 
  
BAR CHART SHOWING PERCENTAGE OF PATIENTS 
IDENTIFIED ON PERRECTAL EXAMINATION AS HAVING 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
82 
PROSTATOMEGALY 
 
NO YES
100%
75%
0%
25%
YES
NO
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TABLE DEPICTING RELATIONSHIP BETWEEN CONTROL  
OF DIABETES AND PRESENCE OF PROSTATOMEGALY 
CROSSTAB FBS / PPBS Total ABNORMAL NORMAL 
Prostato
megly 
NO 
Count 18 31 49 
% with 
PROSTATOMEGALY 36.7% 63.3% 100.0% 
YES 
Count 34 17 51 
% with 
PROSTATOMEGALY 66.7% 33.3% 100.0% 
Total 
Count 52 48 100 
% with 
PROSTATOMEGALY 52.0% 48.0% 100.0% 
Chi-Square=8.970*P=0.003 
In our study, it is evidenced that those patients who had  Diabetes 
of poorer control over a period of time has increasing number of 
prostatomegaly . Similarly, there is very less number of patients with 
prostatomegaly in those who have strict control of Diabetes. 
It is found to be correlating significantly as the p value is < 0.001. 
 
 
 
 
  
BAR CHART DEPICTING RELATIONSHIP BETWEEN 
CONTROL  OF DIABETES AND PRESENCE OF 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NO
84 
PROSTATOMEGALY 
 
YES
37%
67%
63%
33%
 
NORMAL
ABNORMAL
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TABLE CORRELATING REGULARITY OF TREATMENT WITH 
PREVALENCE OF PROSTATOMEGALY 
CROSSTAB 
REGULAR_TT 
Total IRREGUL
AR REGULAR 
Prostato
megaly 
NO 
Count 0 49 49 
% with 
PROSTATOMEGALY 0.0% 100.0% 
100.0
% 
YES 
Count 14 37 51 
% with  
PROSTATOMEGALY 27.5% 72.5% 
100.0
% 
Total 
Count 14 86 100 
% with 
PROSTATOMEGALY 14.0% 86.0% 
100.0
% 
Chi-Square=15.641**P<0.001 
The table depicts that increasing percentage of patients found to 
have prostatomegaly among those on irregular treatment compared to 
patients on regular treatment. Similarly, there is less number of patients 
with Prostatomegaly among those on regular treatment. 
It is found to correlate well significantly as the p value is < 0.001. 
 
  
BAR DIAGRAM CORRELATING REGULARITY OF 
TREATMENT WITH PREVALENCE OF PROSTATOMEGALY
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NO
86 
 
YES
0%
28%
100%
62%
 
REGULAR
IRREGULAR
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TABLE DEPICTING PERCENTAGE OF PATIENTS HAVING 
LOWER URINARY TRACT SYMPTOMS AMONG THOSE WITH 
PROSTATOMEGALY 
CROSSTAB 
LUTS 
SYMPTOMS Total 
NO YES 
Prostato
megaly 
NO 
Count 49 0 49 
% with 
PROSTATOMEGALY 100.0% 0.0% 100.0% 
YES 
Count 24 27 51 
% with 
PROSTATOMEGALY 47.1% 52.9% 100.0% 
Total 
Count 73 27 100 
% with 
PROSTATOMEGALY 73.0% 27.0% 100.0% 
Chi-Square=36.536**P<0.001 
The above table projects the fact that among those patients with 
prostatomegaly, only about 52% patients will present with symptoms of 
lower urinary tract. It is found to correlate well significantly as the p 
value is < 0.001. 
 
 
 
 
  
BAR DIAGRAM 
HAVING LOWER URINARY TRACT SYMPTOMS AMONG 
THOSE WITH PROSTATOMEGALY
 
 
0%
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88 
DEPICTING PERCENTAGE OF PATIENTS 
 
NO YES
100%
48%
0%
52%
 
 
YES
NO
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CROSSTABULATION DEPICTING AGE WISE DISTRIBUTION 
OF PROSTATOMEGALY 
PROSTATOMEGALY * age group 
Crosstabulation 
Age Group 
Total 40-50 
years 
51-60 
years 
Prostatom
egaly 
NO 
Count 27 22 49 
% within 
PROSTATOMEGALY 55.1% 44.9% 100.0% 
YES 
Count 13 38 51 
% within 
PROSTATOMEGALY 25.5% 74.5% 100.0% 
Total 
Count 40 60 100 
% within 
PROSTATOMEGALY 40.0% 60.0% 100.0% 
Chi-Square=9.130**P<0.001 
From the given table, it is evident that among patients with 
prostatomegaly 75% falls within the age group of 50-60 years , compared 
to 25 %  in 40- 50 years patients . It shows that incidence of 
prostatomegaly increases as the age of the patient increases and as the 
control of Diabetes becomes poor. 
It is found to correlate well significantly as the p value is < 0.001. 
 
  
BAR DIAGRAM DEPICTING AGE WISE DISTRIBUTION OF 
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DISCUSSION 
          The study being conducted as a prospective and retrospective 
observational study among  patients attending Diabetology OPD /Institute 
of internal medicine at Madras Medical College and Rajiv Gandhi 
Government General Hospital. The sample size was 100. After getting the 
informed consent of the patients and   their  attending close relatives, the 
patients were subjected to history taking, physical examination and 
relevant laboratory testing  and imging. These were done to identify the 
presence of prostatomegaly and to correlate it with the glycemic profile 
and duration of Diabetes in the patients. 
      Type of Diabetes and associated diabetic complication does not seem 
to have any impact on risk of prostatomegaly and LUTS. Patients with 
Diabetes mellitus more than 6 years duration are found to be associated 
with a higher prevalence of UTI and LUTS secondary to prostatomegaly.  
      Benign prostatic hyperplasia (BPH) is a representative urological 
disease in males at senescence. The etiology of BPH being  
multifactorial, with chronic conditions, like hypertension,  overweight , 
raised low density lipoprotein (LDL) cholesterol levels and a high insulin 
levels, constitutes for the development of BPH. Prevalence of 
hyperglycemia and resistance to insulin in a BPH population was 
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investigated and the relationship among prostatomegly and metabolic 
syndrome tends to correlate well.  
A study done by Kallol Bhattacharjee et al also correlates the 
presence of prostatomegaly with duration of DIABETES and glycemic 
profile. 
       The probability of males with BPH in the presence of  metabolic 
syndrome is high compared to those without metabolic syndrome. 
Consequently, in BPH patients, a very careful evaluation for metabolic 
syndrome is needed, with the early diagnosis and a  proper management 
of metabolic syndrome should accompany the treatment of BPH. 
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The predominant  feature  involving the  genitourinary system in 
males with Diabetes mellitus are lower urinry tract symptoms, retrograde 
ejaculation , erectile dysfunction (ED) and, and dysfunction of bladder. 
Prevalence of 51% prostatomegaly has been recorded in our study in 
patients of age group 40-60 years with Diabetes which is significantly 
increased  than the prevalence (35%) found among general population . 
Since ,plenty of  other factors contribute for the development of 
prostatomegaly, it is prime that males with Diabetes are instructed to 
maintain glycemic control, lifestyle changes such as smoking 
contributing to the progression  of prostatomegaly.  
Reduced bladder sensation , increment in bladder capacity, 
impaired contractility of detrusor muscles are all the charachteristic 
features of diabetic bladder dysfunction. Management strategies are 
aimed at voiding strategies aimed at  symptom relief , prevention of 
infections and maintaining continence. 
  
LIMITATIONS 
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LIMITATIONS OF THE STUDY 
A multi centric study with a larger sample size and further longer 
follow up is essential to assess the predictive power of these 
prognostication tools in a more comprehensive manner. 
 
  
CONCLUSION 
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CONCLUSION 
Benign prostatic hyperplasia and symptoms of lower urinary tract 
are frequently encountered in type 2 diabetic patients.  
  Elderly patients  of age >50 years, longer duration of Diabetes,  
non-adherence to treatment, poor glycemic profile, insulin therapy are all 
a significant risk factor  for the development of  prostatic enlargement and 
thereby, leading on to benign prostatic hyperplasia and lower urinary tact 
symptoms. Uncontrolled blood glucose (FBS/ PPBS) with HbA1 C>7%, 
post void residue >150 ml and prostate volume >40 cc  correlates well. 
       It has become evident clearly from our study that, the presence 
of prostatomegaly correlates well with the glycemic profile and the 
duration of Diabetes mellitus .The prevalence of prostatomegaly is thus, 
found to be increased in type 2 diabetic patients aged 40-60 years. 
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ABBREVIATIONS 
 
DM     -  DIABETES MELLITUS 
BPH    - BENIGN PROSTATIC HYPERPLASIA 
MODY - MATURITY ONSET DIABETES OF YOUNG 
GDM   - GESTATIONAL DIABETES MELLITUS 
ADA    - AMERICAN DIABETES ASSOCIATION 
IDF      - INTERNATIONAL DIABETES FEDERATION 
FPG    - FASTING PLASMA GLUCOSE 
HBA1c  -  GLYCOSYLATED HEMOGLOBIN 
IGT     - IMPAIRED GLUCOSE TOLERANCE 
IFG     - IMPAIRED FASTING GLUCOSE 
BMI    - BODY MASS INDEX 
CRP    - C  REACTIVE PROTEIN 
IAPP   - ISLET AMYLOID POLYPEPTIDE 
GLUT4  -  GLUCOSE TRANSPORTER 4 
CDC    -  CENTER FOR DISEASE CONTROL  
TNF     - TUMOUR NECROSIS FACTOR ALPHA 
HDL   - HIGH DENSITY LIPOPROTEIN 
LDL    - LOW DENSITY LIPOPROTEIN 
BOO   - BLDDER OUTLET OBSTRUCTION 
LUTS  - LOWER URINARY TRACT SYMPTOMS 
 
ANNEXURES 
 
  
  
PROFORMA 
 
NAME OF THE PATIENT     : 
AGE / SEX            : 
OP/ NUMBER       : 
OCCUPATION       : 
ADDRESS        : 
 
 
CONTACT NUMBER      : 
 
COMPLAINTS        
 Urinary frequency 
 Urinary urgency 
 Hesitancy  
 Interrupted, weak stream 
 Incomplete bladder emptying  
 Straining  
 Dribbling  
 
 
 
 
 
  
PAST HISTORY        
K/C/O PROSTATIC 
CARCINOMA 
 
H/O DIABETES 
TYPE 1 / TYPE 2                                        - 
DURATION                                                 - 
ON OHA / INSULIN                                   - 
REGULAR / IRREGULAR TREATMENT   - 
 
 
GENERAL EXAMINATION 
Pallor:               Icterus:            Cyanosis:           Clubbing:          
Lymphadenopathy:         Edema: 
 
VITALS 
Pulse Rate:          BP:          Respiratory rate:        Temperature: 
 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM     : 
 
RESPIRATORY SYSTEM         : 
 
ABDOMEN                 : 
 
  
CENTRAL NERVOUS SYSTEM  : 
                   
 
 
INVESTIGATIONS:   
FASTING BLOOD GLUCOSE  
POSTPRANDIAL BLOOD GLUCOSE 
HBA1c 
SERUM PROSTRATE SPECIFIC ANTIGEN 
( IF APPLICABLE) 
ULTRASONOGRAM OF PELVIS 
            PROSTRATE SIZE/VOLUME 
            POST-RESIDUAL VOLUME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
THESIS APPROVAL CERTIFICATE 
 
 
 
 
 
 
  
 
TURNITIN 
 
 
 
 
  
TURNITIN PLAGIARISM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
INFORMATIONSHEET 
          We are conducting a study on “A STUDY ON PREVALANCE 
OF PROSTATOMEGALY AND ITS CORRELATION WITH 
DURATION AND GLYCEMIC CONTROL IN PATIENTS WITH 
TYPE 2 DIABETES MELLITUS ” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your co- 
operation to undergo FBS/ PPBS , HBA1C , USG OF PELVIS, SERUM 
PSA (if applicable) may be valuable to us. 
           The purpose of this study is to identify the presence of 
prostatomegaly in patients with type 2 diabetes mellitus and correlating it 
with duration and glycemic profile of diabetes  . 
 
We are selecting certain cases and if you are found eligible, we 
would like  to perform extra tests and special studies which in any way do 
not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
 
Signature of Investigator Signature/left thumb impression of 
Participant 
 
 
Date : 
Place  : 
  
  
  
PATIENT CONSENT FORM 
Study Detail : “A STUDY ON PREVALANCE OF 
PROSTATOMEGALY AND ITS CORRELATION 
WITH DURATION AND GLYCEMIC CONTROL IN 
PATIENTS WITH TYPE 2 DIABETES MELLITUS”  
Study Centre : Department of Diabetology,Institute of Internal Medicine, 
Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction.  
  
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected.  
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study.  
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination, and 
necessary investigations.  
 
Signature of Investigator     Signature/thumb impression 
  
Investigator’s Name:            
                                                                      Patient’s Name and Address: 
Dr.S.PRABHAKARAN
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